

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6623812

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>SEQUENCE:</b>	2
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CRYSTAL PHARMATECH INC.	03/25/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	VTV THERAPEUTICS LLC
<b>Street Address:</b>	3980 PREMIER DRIVE, SUITE 310
<b>City:</b>	HIGH POINT
<b>State/Country:</b>	NORTH CAROLINA
<b>Postal Code:</b>	27265
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17030611
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	3368880427
<b>Email:</b>	srollins@vvttherapeutics.com
<b>Correspondent Name:</b>	SAMUEL ROLLINS
<b>Address Line 1:</b>	3980 PREMIER DRIVE, SUITE 310
<b>Address Line 4:</b>	HIGH POINT, NORTH CAROLINA 27265
<b>ATTORNEY DOCKET NUMBER:</b>	4006.204-US
<b>NAME OF SUBMITTER:</b>	SAMUEL B. ROLLINS
<b>SIGNATURE:</b>	/Samuel B. Rollins/
<b>DATE SIGNED:</b>	03/26/2021
<b>Total Attachments: 2</b>	
source=4006_204-PCT-Assignment_Crystal_to_vTv#page1.tif	
source=4006_204-PCT-Assignment_Crystal_to_vTv#page2.tif	

## ASSIGNMENT OF PCT INTERNATIONAL APPLICATION

For good and valuable consideration, the receipt of which is hereby acknowledged, Crystal Pharmatech Inc. a New Jersey corporation, having its principal place of business at 3000 Eastpark Blvd., Suite 500B, Cranbury, New Jersey 08512 ("the Assignor") hereby sells, assigns, and transfers to vTv Therapeutics LLC, a Delaware limited liability company, having its principal place of business at 4170 Mendenhall Oaks Parkway, High Point, North Carolina 27265 ("the Assignee"), and the Assignee's successors and assigns, all right, title, and interest for all countries in and to the PCT international application entitled

PHARMACEUTICALLY ACCEPTABLE SALTS OF [3-(4- {2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4-YL} -PHENOXY)-PROPYL]-DIETHYL-AMINE, filed March 19, 2019, and identified as PCT Patent Application No. PCT/US2019/22933 ("the Application"),

and in and to any and all inventions disclosed in the Application ("the Inventions") and all nonprovisional applications for United States Patent, including divisional, continuing, substitute, renewal, and reissue thereof, and all other applications for United States Patent or other related property rights in any and all foreign countries which have been or shall be filed on one or more of the Inventions, and in and to all original and reissued patents or related foreign documents that have been or shall be issued on one or more of the Inventions.

The Assignor, in accordance with this assignment, authorizes and requests the Commissioner for Patents of the United States to issue to the Assignee or the Assignee's successors and assigns, in accordance with this assignment, any and all United States Patents that claim or disclose one or more of the Inventions.

The Assignor further agrees, for good and valuable consideration, the receipt of which is hereby acknowledged, that the Assignee or the Assignee's successors and assigns may apply for and receive foreign Patents or similar such rights and, in doing so, may make a claim of priority to the Application under the provisions of any bilateral or multilateral treaty or international agreement, including but not limited to, the International Convention of 1883 and later modifications thereof ("the Paris Convention"), the Patent Cooperation Treaty, the European Patent Convention, the Eurasian Patent Convention, the agreement(s) of the African Regional Intellectual Property Organization, the agreement(s) of the Organisation Africaine de la Propriete Intellectuelle, and the agreement(s) of the Cooperation Council for the Arab States of the Gulf; and that, when requested, without charge to the Assignee or the Assignee's successors and assigns, to carry out in good faith the intent and purpose of this assignment, the Assignor will, for the United States and any and all foreign countries: (i) execute any and all documents related to any application for patent in the United States or a foreign country, where such application discloses one or more of the Inventions; (ii) execute any and all oaths, declarations, assignments, confirmatory assignments, powers of attorney and other papers concerning one or more of the Inventions and any and all patent applications thereon, whether in the United States or a foreign country; and (iii) perform other such acts, at the request of the Assignee or the Assignee's successors and assigns, to obtain or maintain any and all patents or related property rights in the United States or any foreign country on one or more of the Inventions or any improvements thereto and to vest title thereto in the Assignee or the Assignee's successors and assigns.

4006.204-PCT

In testimony whereof, I, Yanfeng Zhang (printed name), Chief Scientific Officer (title) of the Assignor, Crystal Pharmatech Inc., have signed my name below on the date indicated on behalf of the Assignor, Crystal Pharmatech Inc. By such signature, I acknowledge that I have actual authority to act on behalf of the Assignor, Crystal Pharmatech Inc., in this capacity.


Yanfeng Zhang

Name (Printed)

Chief Scientific Officer

(Title)

Crystal Pharmatech Inc.

  
Signature

25 MAR 2019  
Date